There are many reasons to own Abbott Laboratories (NYSE: ABT), but they all boil down to one thing: consistent market-beating returns.

Abbott Laboratories has reported sales of $10.6bn for the third quarter (Q3) of 2024, as against $10.4bn in Q2 2024, with ...

Travis Steed, an analyst from Bank of America Securities, reiterated the Buy rating on Abbott Laboratories (ABT – Research Report). The ...

Abbott Laboratories ABT reported better-than-expected third-quarter results on Wednesday. The company posted sales of $10.64 ...

Q3 2024 Earnings Call Transcript October 16, 2024 Abbott Laboratories beats earnings expectations. Reported EPS is $1.21, ...

United Airlines Holdings is up more than +8% after reporting stronger-than-expected Q3 adjusted EPS and initiating a $1.5 billion stock buyback program. Also, bank stocks are climbing today after ...

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, ...

Wall Street trading got off to a mixed start on Wednesday as the Dow Jones tried to claw back some of the heavy losses ...

Abbott Laboratories earnings slightly topped Q3 views, with medical devices leading organic sales growth. Abbott stock edged lower.

Morgan Stanley (NYSE:MS) stock rose 4% after the lender's profit surpassed estimates on a bumper third quarter for investment ...

Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results ...

Abbott Laboratories on Wednesday reported better-than-expected third-quarter earnings and sales, boosted by strength in the ...